Science Rocks! An AbbVie Scientist Ranks the Reality of Innovations Predicted for 2018

A wearable patch for sleep apnea. Scalp cooling for chemotherapy patients. An AbbVie scientist weighs in on medical innovations coming in 2018.

science_rocks_hero_v3.jpg

Science Rocks features AbbVie scientists who share interesting research in their field and why it matters. In this month's feature, Christopher Miller, Ph.D, a director in The Genomics Research Center within target enabling science and technologies, recently discussed gene editing at the Cleveland Clinic Medical Innovation Summit. After his presentation, he stuck around to hear the top 10 medical innovations for 2018, as predicted by the Cleveland Clinic. Here’s what he thinks:

The world’s first artificial pancreas.

A wearable patch to help sleep apnea.

Gene therapy for blindness.

The Cleveland Clinic unveiled their top 10 medical innovations of 2018 at this year’s Medical Innovation Summit. At the Summit, I sat on a panel that discussed gene editing and gene therapy, but was also interested in their list of potential breakthroughs for next year.

Being a scientist, of course, I have some thoughts of my own. While this year’s innovations cover a variety of potential innovations including pharmaceutical therapies, medical devices and medical practices and procedures, one thing is clear – all have the potential to profoundly impact patient care and treatment.

Each of the new pharmaceutical therapies could be game-changing. The field of gene therapy has made important advances, but has also suffered some high profile setbacks. Gene therapy to treat eye diseases has some advantages based on accessibility and anatomy of the eye and the existence of several genetically-based eye diseases for which replacement of a defective gene has been shown to be curative. The best known examples of this are Leber Congenital Amaurosis and Retinitis Pigmentosis, both caused by RPE65 mutations. Gene therapy to deliver normal RPE65 has been shown to overcome disease in human clinical trials with FDA approval anticipated in 2018. If this happens, it would be a win for the gene therapy field and for patients suffering from these diseases.

Next year’s innovations ... all have the potential to profoundly impact patient care and treatment. Each of the new pharmaceutical therapies could be game-changing.

Christopher Miller, Ph.D, director, discovery, Genomics Research Center, AbbVie

Among the medical devices on the list, the most impressive is a closed-loop insulin delivery system in which the insulin pump is directly controlled by a continuous glucose-monitoring device, thereby removing the need for diabetic patients to determine how much insulin to inject. The device had been approved by the FDA in 2016, but hadn’t achieved widespread use. This is predicted to change in 2018 as more patients learn about the devices and more insurers provide reimbursement. Other devices on the list include an implanted device that delivers stimulation to muscles to open airways during sleep. Since sleep disorders are on the rise and poor sleep is connected to many chronic diseases, this innovation could have widespread positive impact on patients with sleep disorders (and their spouses).

All of these innovations have the potential to be transformative in their own ways to save lives and improve the quality of life. It will be interesting to see how these play out in 2018 and to see what the lists look like for 2019 and beyond.

Fun Facts About Me:

Media inquiries

 

Sign Up

Jaquelin Finley
Email: Jaquelin.finley@abbvie.com
Call: +1 847-937-4111
  Stay up to date on recent news, stories and more by signing up for our topic alerts.
Tags: Perspectives
Share this Story: Share to Facebook Share to Twitter Share to Linkedin Email